Navigation Links
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
Date:3/10/2016

NEW YORK, March 10, 2016 /PRNewswire/ --

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

Summary

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations.

Scope

The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5% -
- How will immunotherapies such as Keytruda affect growth?
- What effect will patent expirations of Tarceva and Alimta have on market value?
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market -
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period -
- How have promising late-stage therapies performed in clinical trials?
- How would the approval of Rociletinib affect the competitive landscape?
- What is the individual commercial forecast for each therapy?
The market forecasts indicate that the US contributes the most to global market value due to a large treatment population and the high price of premium therapies.
- How will ACoT and market size vary between the eight major markets?
- How could a change in risk factors such as population age or smoking habits influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts across the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug contributions to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.
Read the full report: http://www.reportlinker.com/p03311737-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
2. Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
5. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
6. The Combined Non-Small-Cell Lung Cancer Market of Argentina, Brazil and Mexico Will Grow at Six Percent Annually Through 2018
7. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
8. Global Non-small Cell Lung Cancer Market 2014-2018
9. AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress
10. AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
11. New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 04, 2020 , ... ... 2016 and has continued to refine their medical device assessment and penetration ... medical device manufacturing facilities to provide testing onsite, at client facilities. Due ...
(Date:8/5/2020)... ... August 04, 2020 , ... Millions of America’s ... their health and quality of life unless Congress and the Centers for Medicare ... (ASHA) warns today. , At issue is CMS’s 2021 proposed Medicare ...
(Date:8/3/2020)... S.C. (PRWEB) , ... August 03, 2020 , ... Hide-a-Mask, ... Kickstarter raising over $36,000 in less than three weeks since launch. Hide-a-Mask is ... “We are grateful for our early backers who, like us, believe having a mask ...
Breaking Medicine Technology:
(Date:8/11/2020)... (PRWEB) , ... August 11, 2020 , ... Help.org ... ones, has announced the Best Rehab Facilities in Greenville, for 2020. The informational ... services and more. , According to recent studies , drug overdose is ...
(Date:8/11/2020)... ... August 11, 2020 , ... 2020 has seen a drastic change in how things are ... recommended that everyone wears a face mask in public. Now, most states have made it ... , Earlier this year, all medical professionals in the U.S.A realized the shortage of PPE ...
(Date:8/9/2020)... , ... August 10, 2020 , ... Dr. Angela Abraham ... College of Optometry (NECO). Dr. Abraham will be leading the drive to foster a ... signed on to the 13% Promise, a new initiative led by Black Eyecare Perspective ...
(Date:8/7/2020)... (PRWEB) , ... August 07, 2020 , ... ... Duke Street in Alexandria, Virginia. Led by Dr. Mojgan Mazhari, this well-respected practice ... Alexandria Dental Health & Smile Studio is among an exclusive group of dental ...
(Date:8/5/2020)... LOS ANGELES (PRWEB) , ... August 05, 2020 ... ... most used Social Emotional Learning (SEL) program, has been named to the inaugural ... of School Librarians (AASL). , This recognition honors electronic resources that provide ...
Breaking Medicine News(10 mins):